Jiahui International Cancer Center Welcomes Historic First Patient for Groundbreaking CAR-T Therapy
SHANGHAI, July 6, 2026 – In a groundbreaking development for oncology and a significant milestone for medical advancements in China, the Jiahui International Cancer Center (JICC) has received its first international patient to commence treatment with Satri-cel, the world’s first approved chimeric antigen receptor T-cell (CAR-T) therapy specifically designed for solid tumors. This historic event not only showcases China’s burgeoning reputation as a leader in cancer research and treatment but also opens vital new avenues for international patients pursuing innovative therapies.
The inaugural patient, identified as Josh, is a 59-year-old man from New Zealand, grappling with advanced gastroduodenal cancer. Faced with increasingly limited conventional treatment options back home, Josh made the journey to Shanghai in search of more progressive solutions. Following thorough biomarker testing, which confirmed the presence of Claudin 18.2 and the absence of HER2, he qualified for the newly approved Satri-cel therapy, currently licensed for use only in China.
Upon arrival at JICC, Josh underwent a complete multidisciplinary evaluation and a treatment planning process tailored to his specific health needs. He has successfully completed leukapheresis, a procedure in which blood is drawn from the patient, and the T-cells are harvested — these cells have since entered the manufacturing process. The next critical step will be the reinfusion of his personalized CAR-T cells, which is scheduled to occur in the forthcoming weeks.
The approval of Satri-cel marks a monumental leap in the field of cellular immunotherapy, occurring just days prior to Josh’s treatment initiation. This innovative therapeutic approach signifies a substantial advancement in the fight against solid tumors, historically deemed more challenging to address than hematological malignancies. “The approval of Satri-cel represents not just a significant milestone for patients suffering from advanced gastric cancer, but also hints at the future trajectory of oncology on a global scale,” noted Dr. Linli Xuan, Chief of Medical Oncology at Jiahui International Cancer Center. “It is our privilege that JICC has been selected as the first center for international patients like Josh to access this pioneering treatment.”
As one of China’s premier international cancer treatment facilities, JICC has positioned itself as a prominent gateway for patients from various countries seeking advanced therapies stemming from robust Chinese research and innovation. Their commitment extends beyond medical excellence; JICC provides comprehensive support for international patients through a dedicated International Patient Office, which offers an array of services including medical record review, specialist consultations, logistical assistance, and integrated follow-up care. These resources facilitate a seamless experience for patients navigating unfamiliar healthcare landscapes far from home.
The advent of Satri-cel is expected to draw increasing interest from patients around the globe. As the therapeutic landscape evolves, the international medical community is keenly observing China’s developments in oncology, particularly in areas that emphasize novel treatments and advanced therapeutic techniques. The ability to provide cutting-edge therapies situated within a supportive and comprehensive care framework positions JICC as a beacon for patients seeking hope amidst challenging diagnoses.
However, it is critical to highlight that access to such pioneering therapies remains a pressing concern for many around the world. Despite the advancements being made within China’s healthcare system and its commitment to international patients, disparities in medical access persist, urging a collective effort towards equitable healthcare solutions. As the conversation around global health continues to expand, the significance of institutions like Jiahui International Cancer Center cannot be understated, balancing the intersection between advanced medical treatment and compassionate patient care.
For those seeking more information about Jiahui International Cancer Center and the services offered, inquiries may be directed to the International Patient Office via email at internationaloffice@jiahui.com, or through WhatsApp at +852 4619 1904.
The path forward in oncology is undeniably complex, yet with pioneering treatments like Satri-cel, it is clear that innovative strides are being made, reshaping the future of cancer care across the globe.
—
Tags: #HealthNews, #BusinessNews, #EconomyNews, #China